INTRODUCTION
Recurrent chromosomal abnormalities in the malignant cells of patients with acute leukemia are hallmarks of the disease. 1 Specific aberrations, which are frequently indicative of consistent underlying molecular lesions, can assist or even establish the diagnosis and determine optimal therapy. In childhood acute lymphoblastic leukemia (ALL) numerous good and high risk cytogenetic subgroups have been identified which are regularly used to stratify patients to particular therapies. 2 However, in adult ALL the role of cytogenetics in patient management has largely been centred on the presence of the Philadelphia (Ph) chromosome which usually arises from t(9;22)(q34;q11.2) and results in BCR-ABL fusion. 3 Although the overall incidence of Ph+ ALL in adults is approximately 25%, it is correlated with age and rises to more than 50% among patients over the age of 55 years. 4 Even though other recurrent chromosomal abnormalities have been described in adult ALL, their frequency has been low and their prognostic relevance unclear. Indeed, some aberrations have been reported variously as good and poor risk by different study groups. [5] [6] [7] [8] [9] [10] One of the principal hurdles in developing a more sophisticated cytogenetic profile of adult ALL and assessing the utility of cytogenetics in predicting outcome is due to the rarity of this disease (less than one case per 100,000 person-years). 11 This situation is exacerbated by the fact that apart from the Ph each of the other recurrent abnormalities accounts for less than 10% of the total. These two factors necessitate the acquisition of large cohorts of patients which have undergone prospective cytogenetic analysis. The majority of previous published studies have either concentrated solely on the presence of the Ph or comprised cohorts too small to accurately assess the outcome of rare cytogenetic subgroups. In this report we present cytogenetic results from a large multi-centre international treatment trial of adult ALL -Medical Research Council (MRC) UKALLXII / Eastern Cooperative Oncology Group (ECOG) 2993. [12] [13] [14] A total of 1,522 patients have been registered on this trial and pretreatment cytogenetic analysis was attempted in 90% of cases. The frequency, clinical features and prognostic relevance of over 20 cytogenetic subgroups are reported.
PATIENTS AND METHODS

Patients
The MRC UKALLXII / ECOG E2993 trial started recruiting patients diagnosed with ALL in January 1993. [12] [13] [14] Patients between 15 and 55 (MRC) or 65 (ECOG) years of age were eligible for this study irrespective of their prognostic factors at presentation, including those Full details of the protocol have been previously published. [12] [13] [14] Briefly, patients received two phases of standard induction therapy. Patients with an HLA-matched family donor were assigned to an allogeneic bone marrow transplant. Ph+ patients could also receive an allogeneic transplant from a matched unrelated donor. All other patients were randomized to standard consolidation/maintenance chemotherapy or a single autologous transplant. Prior to the assigned or randomized therapy, all patients received intensification with three courses of high-dose methotrexate. The study was approved by the institutional review board of each treatment centre and informed consent was given. The current study focuses on 1,522 patients registered before the revision to incorporate Imatinib for Ph+ patients (MRC -May 2003,
ECOG -May 2004).
Cytogenetic and Molecular Genetic Analysis
Pre-treatment bone marrow (BM) or peripheral blood (PB) samples taken at diagnosis were cultured and analyzed by standard cytogenetic methods at local laboratories. Slides and/or karyograms were centrally reviewed either by the Leukaemia Research Cytogenetics Group (LRCG) 15 or the ECOG Cytogenetics Subcommittee. All karyotypes were described according to the International System for Human Cytogenetic Nomenclature. 16 Where possible, diagnostic samples were also tested for the presence of the BCR-ABL fusion gene by 
Statistical Analysis
The relationships between cytogenetic subgroups and gender and T-cell status were analysed using the Chi-squared test, whereas the t-test was used to compare continuous variables such (13%-25%), P=0.09]. However, the effect was not independent of age or WCC and disappeared when transplanted patients were removed from the analysis.
RESULTS
Conventional Cytogenetic Analysis
Patients with t(4;11)(q21;q23) and other MLL/11q23 translocations
A total of 69 (9%) Ph-patients had a translocation involving the MLL gene located at 11q23.
The majority (n=54) had t(4;11) (Table 1) while the remainder had other translocations, including six with t(11;19)(q23;p13.3). All patients with an 11q23 translocation had a significantly higher WCC, but only those with a t(4;11) showed a female predominance or were older (Table 2) (Table 3) .
Patients with t(8;14)(q24.1;q32)
Only 16 patients with t(8;14) or variant of this translocation were registered on this trial accounting for 2% of the Ph-cohort. While the majority (10/16, 63%) had the classic t(8;14), five had t(8;22)(q24.1;q11) and one had t(2;8)(p12;q24.1). Eight of these patients had a mature-B immunophenotype while the remaining patients were classified as either common (n=5) or pre-B (n=3). The outcome of this small subgroup was extremely poor compared with only.
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All but one of the deaths occurred in the first year after diagnosis.
Patients with low hypodiploidy / near-triploidy
The two ploidy subgroups, low hypodiploidy and near triploidy, were combined into a single subgroup (Ho-Tr) because patients with these karyotypes have recently been shown to represent a single distinct subtype of adult ALL. 19 No patients with a near-haploid clone (<30 chromosomes) were detected in this cohort. Within the Ph-cohort, 31 (4%) patients had a
Ho-Tr karyotype and none harboured any established translocation (Table 1 ). Cytogenetic analysis revealed the presence of both sub-clones in six patients whereas in the remaining 25 patients only the low hypodiploid (n=6) or near-triploid (n=19) sub-clone was detected.
Patients in this subgroup had a significantly lower WCC compared with other Ph-patients and were less likely to have T-ALL ( Table 2) . Patients with Ho-Tr had a significantly inferior EFS and OS compared with other Ph-patients (Table 3 ). Five (16%) patients failed to achieve remission. Among patients that did achieve a CR, 13/26 (50%) relapsed and a further seven (27%) died in remission within 1 year of diagnosis. The majority of relapses involved an isolated BM relapse (12/13). The median time to relapse was 9 months and was followed by death in every case. The 5 year OS for Ho-Tr patients is 22% and only six (19%) are still in CCR (Table 3 ). There was no difference in outcome between those that presented with a low hypodiploid sub-clone and those that presented solely with a near-triploid sub-clone.
Patients with a complex karyotype
In the Ph-cohort, a total of 41 (5%) patients, without an established translocation, had a complex karyotype with five or more chromosomal abnormalities (Table 1) . Although patients in this subgroup were not associated with any particular gender, age, WCC or T-cell status (Table 2 ) they had a significantly inferior EFS and OS ( HeH was the most prevalent specific chromosomal abnormality in the Ph-cohort occurring in 77 (10%) patients, occasionally in conjunction with established translocations (Table 1) . HeH patients were significantly younger, had a lower WCC and incidence of T-cell disease compared with other Ph-patients (Table 2) . They had significantly improved EFS and OS compared to other patients in this cohort (Table 3) . Virtually all HeH patients who relapsed subsequently died (19/21) but their relapse rate at 5 years was significantly lower than other Ph-patients [34% (24%-48%) versus 50% (45%-54%), p=0.007]. The median time to relapse among HeH patients was 1.4 years compared to less than 1 year for non-HeH patients.
Patients with deleted 9p
Deletions of 9p were observed in 71 (9%) Ph-patients, were the second most prevalent abnormality and were frequently a secondary aberration (Table 1) . Patients with del(9p) were marginally younger than other Ph-patients and had an improved EFS (Tables 2 and 3 ). They were significantly less likely to die (OS at 5 years 58% (45%-69%) versus 40% (36%-44%), p=0.03) compared to other Ph-patients.
Patients with other chromosomal abnormalities
In addition to the chromosomal abnormalities discussed above we examined the demographic, clinical and survival profiles of Ph-patients with 16 other specific cytogenetic abnormalities (Tables 1-3 ). Although several subgroups showed distinct gender, age, WCC or T-cell status profiles, none of these cytogenetic subgroups showed any significant association with disease outcome.
Multivariate analysis
We used a Cox proportional hazards model to assess the prognostic relevance of cytogenetic variables within the Ph-cohort in the context of other established survival indicators: gender, age, WCC and T-cell status (Table 4) . Age, WCC and T-cell status were strong predictors of outcome for both EFS and OS, but gender was only relevant with respect to OS. Females were more likely to have died compared to males (64% versus 56%, p=0.022), however this is, in part, explained by the fact that females in this cohort were significantly older than their male counterparts (33 year versus 30 years, p<0.0001). The adverse effect of t(8;14), Ho-Tr and complex karyotype was shown to be independent of age, gender, WCC and T-cell status (Table 4 ). This was true of both EFS and OS. Patients with t(8;14) had more than a two-fold increased risk of suffering an adverse event whereas those with a Ho-Tr or complex Ph-patients in this study were either biologically selected or randomised to undergo a BM transplant as part of their treatment and cytogenetics was not used to assign therapy. In order to account for treatment heterogeneity, we rebuilt the final EFS and OS models excluding patients who received a transplant in first CR (n=289) from the EFS model and all transplanted patients (n=359) from the OS model. These exclusions made no difference to the prognostic relevance of the three significant cytogenetic variables: t(8;14), Ho-Tr and complex karyotype.
DISCUSSION
The results of this study provide compelling evidence for the importance of cytogenetics in predicting prognosis in adult ALL. Ph+ and Ph-patients were analysed separately with respect to survival because the presence of the Ph chromosome was used to direct therapy.
This approach meant that the prognostic relevance of cytogenetic subgroups could be ascertained accurately without their effect being masked by the strong and established poor outcome associated with Ph+ ALL. Univariate analysis showed that within the Ph-cohort patients with t(4;11), t(8;14), complex karyotype and Ho-Tr had an inferior outcome while those with HeH and del(9p) fared better. Moreover, the three cytogenetic variables, t(8;14), complex karyotype and Ho-Tr, were shown to be independent prognostic factors. As this was a randomised trial, patients were either biologically selected or randomised to receive a BM transplant. 12 Therefore, the multivariate analysis (Table 4) is valid despite treatment heterogeneity. The large number of patients available for analysis enabled us to exclude from these models patients who received a transplant. The observation that the exclusion of these only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From patients did not alter the prognostic relevance of three cytogenetic subgroups confirms that transplant-related mortality was not biasing our results. Too few patients in the prognostically relevant cytogenetic subgroups underwent a transplant for us to evaluate whether an allogenic BMT would alter the outcome of these high risk patients. The rarity of these cytogenetic subgroups means that a meta-analysis is needed to clarify the effect of transplant.
Patients with t(4;11) in this study, like previous studies 5-7;10 , had a shorter survival but the effect was not independent of age and WCC. However, both age and WCC are strongly correlated with this abnormality. Although based on relatively small numbers of patients, additional analyses showed that t(4;11) patients with a low WCC still had a very poor outcome, while younger t(4;11) patients probably fared worse than their age matched counterparts. This analysis highlights the difficulty of confirming the independent prognostic importance of relatively small cytogenetics subgroups which are strongly correlated with other risk factors such as WCC and age. Our evidence coupled with results from previous studies 5-7;10 indicates that all patients with t(4;11) have an inferior outcome. This conclusion is consistent with the view that cytogenetics, which is a fundamental biological marker of leukaemogenesis, is likely to emerge as a more important indicator of poor prognosis than surrogate markers such as WCC.
A total of 16 patients with t(8;14) or a variant were treated on the early part of this trial.
Interestingly only half of these patients had a mature-B immunophenotype and among patients with common/pre-B ALL the involvement of the MYC gene had been confirmed in two patients (data not shown). This is not the first time that the t(8;14) has been reported outside the context of mature-B ALL. 24 The very poor outcome of this subgroup reflects the fact that patients with t(8;14) / mature-B ALL are now usually treated on lymphoma-like protocols. 25;26 There were too few survivors from this cohort to ascertain whether t(8;14) with or without mature-B ALL had a differential survival.
Recently, Charrin et al reported that patients with low hypodiploidy and near-triploidy represent two sides of a distinct biological subgroup. 19 Therefore, we incorporated this novel grouping into our classification system and showed that like the LALA94 patients, our Ho-Tr patients had a significantly reduced EFS and OS. However, we were also able to demonstrate that this adverse effect was independent of age and WCC. These observations are consistent with previous studies which have examined the prognosis of these ploidy subgroups Only two cytogenetic subgroups, HeH and del(9p), were associated with an improved EFS or OS, although the del(9p) association was marginal. However, these two subgroups did occur in approximately 10% of Ph-patients, albeit occasionally in conjunction with other abnormalities. Both these subgroups were associated with good risk features (low WCC or younger age) and neither subgroup retained its significance in multivariate analysis. HeH is common in childhood ALL and associated with a very good outcome. 21 Therefore, it is not surprising that adults with HeH should be younger than the rest of the cohort and have a better survival. In contrast, del(9p) in childhood ALL is associated with a poor outcome, however, it is more prevalent among T-ALL patients which in turn have a poor outcome. 29;30 Good risk cytogenetic abnormalities have rarely been reported in adult ALL but where these two subgroups have been studied before, the trend has been towards an improved outcome.
5-7;10
The incidence of Ph+ ALL was higher among ECOG patients compared with MRC patients. This is explained, in part, by the facts that ECOG patients were significantly older than their MRC counterparts (mean age 36 versus 31 years, P<0.01) and that its incidence increased with age. The proportion of Ph+ patients in previous studies ranges from 11% to 29%. [5] [6] [7] [8] [9] [10] In keeping with our data, those studies with a low incidence of Ph+ ALL also showed a lower median age and vice versa. As expected, Ph+ patients had significantly inferior EFS and OS compared with Ph-patients. This effect was independent of age and WCC, both of which are only.
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Ph. There are differences between the two cohorts and in the methods of analysis. In the CALGB study the association of -7 with a poor outcome was restricted to a reduced CR rate and limited to patients with -7 as the sole additional abnormality which meant the result was based on just nine patients. In addition, the median age of the CALGB cohort was 46 years compared to 39 years in ours. The results from our study are strengthened by being based on a larger cohort all treated on a single protocol.
Over the past decade there have been only four large trial-based cytogenetic studies of adult ALL 5-7;10 , although two other studies have incorporated limited cytogenetic data. 8;9 The paucity of studies is due to the rarity of the disease and the assumption that cytogenetic indicators of prognosis are limited to the Ph+ and possibly t(4;11). The prognostic relevance of other cytogenetic subgroups has been uncertain, with the same abnormality being reported as both good and poor risk in different studies. 5-7;10 The scale of this trial coupled with prospective central karyotype review contributed to the creation of the largest and most comprehensive cytogenetic dataset of adult ALL. The absolute number of cases with cytogenetics exceeds that accrued by similar studies while the proportion of cases that met the cytogenetic entry criteria compares favourably. 5-7;10 In spite of this 27% cases did not meet our entry requirements, and while this figure is comparable with other studies 5-7;10 , it is too high and greater than seen in childhood ALL. Interestingly, the proportion of cases meeting the entry criteria did not increase over the length of the study, in contrast to the improving results over the some period in childhood ALL. Data from MRC patients strongly indicated that BM samples are preferable to blood samples. The abnormality rate within this cohort was nearly 80%, which again compares favourably with previous studies which have reported rates of 66%-85%. 5-7;10 Routine FISH screening of future cases with probes to genes known to be involved in ALL should help to increase the usefulness of cytogenetics in adult ALL as similar strategies have done in childhood ALL. 32 The cytogenetic classification system presented identified a wide spectrum of specific structural and numerical chromosomal abnormalities in this disease. We did not restrict the classification to the expected common abnormalities included in most studies but also grouped karyotypes according to the presence of 14q32 translocations, del(7p), del(13q)/-13, low hypodiploidy/near-triploid (Ho-Tr) and complex karyotype. The classification used in only.
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5-7;10;33 Although we approached our analysis differently by considering Ph+ and Ph-patients separately, this should not have affected our findings. The majority of aberrations listed above were negatively associated with outcome, hence the removal of poor risk patients from the analysis should have served to accentuate these differences rather than diminish them. Both the GFCH 5 and MRC UKALLXA 6 studies found that the prognosis of patients with 11q23 translocations other than t(4;11) was also poor. In this study these patients did not have a significantly inferior survival. The prognostic relevance of t(1;19) is ambiguous with the GFCH and GIMEMA studies 5;10 reporting it as a poor risk abnormality while the MRC UKALLXA study 6 found it to be associated with a favourable outcome. However, these studies were based on just 11, 7
and 10 patients respectively. In our cohort, the outcome of 28 t(1;19) patients was not significantly different from other Ph-patients.
Monosomy 7 has been reported to be associated with shorter survival whether it occurs with or without a Ph chromosome. 7 However, in our analysis of Ph-patients with -7 fared equally as well as other Ph-patients. Similarly patients with +8 have been reported to have an inferior outcome by CALGB 7 and although our +8 patients did have a slightly lower EFS and OS the difference was not statistically significant. Mancini et al 33 reported that patients with a del(6q) were associated with a T-cell phenotype and inferior prognosis. While we confirmed the association between del(6q) and T-cell ALL, we did not observe a similar decrease in survival.
In conclusion, this large cohort of adult ALL with high-quality cytogenetic data demonstrates the value of cytogenetics for identifying patients at greatest and least risk of treatment failure.
Future randomised clinical trials of adult ALL can and should utilise cytogenetic data to stratify patients into appropriate risk groups in order that they may receive the most effective therapy. Additional cytogenetic and molecular genetic studies of adult ALL are urgently required to further characterise this disease, thereby increasing the number of patients that can benefit from alternative treatment strategies. Philadelphia-negative cases with a successful cytogenetic result; 3 These groups exclude cases with low hypodiploid/near triploidy, high hyperdiploidy and tetraploidy;
4 Abnormal karyotypes excluding those with any of the above abnormalities;
5 Observed/Expected ratios and P value derived from the log rank test comparing the outcome of each cytogenetic group to all other Philadelphia-negative patients with a successful cytogenetic result, except for the total group which was compared to patients with a failed cytogenetic result or without cytogenetics. 
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